To
order this 540+ page report, please visit this - https://www.rootsanalysis.com/reports/view_document/large-volume-wearable-injectors/238.html
Key
Inclusions
§
An overview of
current market landscape of the large volume wearable injectors available for
delivery of insulin and non-insulin drugs, providing information on status of
development and device specifications, such as type of device (patch pump /
injector and infusion pump / injector), type of dose administered (basal, bolus
and others), route of administration (subcutaneous and others), mode of
injection (needle, needle / cannula and needle / catheter), storage capacity of
the device, actuation mechanism (electromechanical, rotary pump, cell /
expanded battery, pressurized gas, osmotic pressure and others), usability
(disposable and reusable), availability of prefilled drug reservoir and
availability of device connectivity. The report also features additional
information on availability of prefilled insulin cartridges, availability of
continuous glucose monitoring / blood glucose monitoring (CGM / BGM) systems,
availability of Automated Insulin Delivery feature and type of remote control
features (control within device / personal diabetes manager (PDM) / smartphone)
in the insulin delivery devices.
§
A detailed
competitiveness analysis of large volume wearable injectors based on various
relevant parameters, such as supplier power (based on the experience /
expertise of the developer) and product specifications (type of device, type of
dose, storage capacity of the device, usability, route of administration,
connectivity and availability of a continuous glucose monitoring / blood
glucose monitoring (CGM / BGM) systems (in case of insulin devices).
§
Elaborate profiles of
the prominent companies that develop large volume wearable injectors. Each
company profile features a brief overview of the company, its financial
information (if available), information on its product portfolio, recent
developments and an informed future outlook. Additionally, the report includes
tabulated profiles of wearable drug device combination products.
§
An analysis of the
partnerships that have been inked by the stakeholders in this domain, during
the period between 2015 and 2020, covering acquisitions, product development
agreements, product integration agreements, technology integration agreements,
distribution and supply agreements, commercialization agreements, clinical
trial agreements, licensing agreements, manufacturing agreements, service agreements, and other relevant types
of deals.
§
A detailed analysis
on acquisition targets, taking into consideration the historical trend of the
activity of the companies that have acquired other firms since 2000, and
offering a means for other industry stakeholders to identify potential
acquisition targets.
§
An in-depth analysis
of the various patents that have been submitted / filed related to large volume
wearable injectors over the last three decades. It also highlights the key
parameters associated with the patents, including information on patent type,
issuing authority / patent offices involved, Cooperative Patent Classification
(CPC) symbols, emerging areas (in terms of number of patents filed / granted),
company type and leading industry, non-industry and individual patent assignees
(in terms of size of intellectual property portfolio).
§
A list of marketed
drugs / therapies and pipeline candidates that are likely to be developed in
combination with large volume wearable injectors in the near future, identified
on the basis of an in-depth analysis of potential candidates, taking into
consideration multiple parameters, such as stage of development, dosage, dose
concentration, route of administration, type of dose and drug sales (in case of
marketed drugs).
§
A social media
analysis depicting prevalent and emerging trends, and the popularity of large
volume wearable injectors, as observed on the social media platform, Twitter.
The analysis was based on tweets posted on the platform in the last few years.
§
A detailed analysis
of completed, ongoing and planned clinical trials of various large volume
wearable injector products based on the various relevant parameters, such as
trial registration year, current trial phase, trial status, study design, study
focus, targeted therapeutic area and clinical outcomes.
§
A case study on the
role of contract manufacturing organizations in the overall manufacturing
process / supply chain of wearable injectors. It includes information on the
services provided by contract service providers for manufacturing of various
device components (primary containers), infusion sets, adhesives, closures and
injection moldings.
§
An elaborate
discussion on the various guidelines established by major regulatory bodies for
medical device approval across North America (the US, Canada and Mexico),
Europe (the UK, France, Germany, Italy, Spain and rest of Europe), Asia-Pacific
and rest of the world (Australia, Brazil, China, India, Israel, Japan, New
Zealand, Singapore, South Africa, South Korea, Taiwan, and Thailand). The
report also features an insightful multi-dimensional, heat map analysis,
featuring a comparison of the contemporary regulatory and reimbursement
scenarios in key geographies across the globe.
§
Informed estimates of the existing
market size and the future opportunity for large volume wearable injectors,
over the next decade. Based on parameters, such as the number of commercialized
devices, number of devices under development, price of the device and the annual
adoption rate, we have provided an estimate on the likely evolution of the large
volume wearable injectors market, for the delivery of both insulin and
non-insulin drugs, over the period 2020-2030.
The report features the likely distribution of the
current and forecasted opportunity across important market segments, mentioned
below:
§ Type
of Device
- Patch Pump / Injectors
- Infusion Pump / Injectors
§ Product
Usability
§ Therapeutic
Area (for non-insulin drugs)
- Neurological Disorders
- Cardiovascular Disorders
- Oncological Disorders
- Infectious Disorders
§
Key geographical regions
- North America
- Europe
- Asia Pacific
The
report features inputs from eminent industry stakeholders, according to whom, large
volume injectors are generally preferred for the delivery of biologics, which
cannot be easily administered orally. The report includes detailed transcripts
of discussions held with the following experts:
§
Mark Banister (CEO, Medipacs)
§
Michael Hooven (CEO, Enable Injections)
§
Jesper Roested (CEO, Subcuject)
§
Pieter Muntendam (Former President and CEO, scPharmaceuticals)
§
Menachem Zucker (Vice President and Chief Scientist, Elcam Medical)
§
Graham Reynolds (Vice President and General Manager, Biologics, West Pharmaceutical Services)
§
Mindy Katz (Director of Product, Sorrel
Medical)
To request sample pages, please visit this - https://www.rootsanalysis.com/reports/238/request-sample.html
Key
Questions Answered
§
Who are the leading developers of large volume wearable devices?
§
What are the prevalent trends within the large volume wearable
injectors market?
§
Which drug candidates are suited for delivery via large volume
wearable injectors?
§
Who are the key contract service providers in this domain?
§
What are the various regulatory guidelines issued for medical
devices across different regions?
§
How is the current and future market opportunity likely to be
distributed across key market segments?
You may also be interested in the
following titles:
- Microneedles and
Needle-Free Injection Systems
/ Jet Injectors (Devices based on Spring, Gas and Other Mechanisms)
Market, 2019-2030 [COVID-19 Series]
2.
Global Autoinjectors Market (3rd Edition), 2020-2030
3.
Prefilled Syringes
Market (5th Edition), 2020-2030
Contact Us:
Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091
Gaurav.Chaudhary@rootsanalysis.com